ArticleFrontiers in public health2026
Investigation and analysis of pertussis antibody levels among healthy people in Hangzhou, Zhejiang Province from 2021 to 2024.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study aims to investigate the levels of pertussis antibodies among the healthy population in Hangzhou, Zhejiang Province from 2021 to 2024. The goal is to understand the immune status of the population regarding pertussis, providing a basis for assessing the epidemiological risk of pertussis. Methods: A multi-stage stratified sampling method was employed, categorizing the population into 11 age groups. From 2021 to 2024, one district/county was selected each year to collect blood samples from healthy individuals. Enzyme-linked immunosorbent assay (ELISA) was used to detect serum pertussis Immunoglobulin G (IgG) antibodies. Results: A total of 1,352 participants were included in the study. A definite history of vaccination was documented in 65.09% of the study subjects. The overall positive rate of antibodies in the healthy population was 37.50%, with a geometric mean concentration (GMC) of 51.54 U/mL (95% CI: 47.82-55.34). Statistically significant differences were observed in the positive rates and GMC values of pertussis IgG across different years, age groups, vaccination histories, and intervals between primary and last doses. Notably, the positive rate and GMC value in 2023 and when the interval between the first and last doses was less than 1 year were the highest within the corresponding subgroups ( Conclusion: Suboptimal pertussis antibody levels in specific age groups, particularly among adolescents and adults, may contribute to an increased risk of transmission. Therefore, it may be worthwhile to consider booster vaccinations for these at-risk populations including the introduction of the vaccine for adolescents and adults, such as Tdap vaccine. In parallel, establishing a standardized testing and surveillance system would be essential for evaluating population immunity and mitigating future outbreak risks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.